156 related articles for article (PubMed ID: 12852346)
1. [Hypersensitivity reactions to cancer chemotherapeutic agents].
Sato A; Sakashita A; Taguchi S
Gan To Kagaku Ryoho; 2003 Jun; 30(6):793-800. PubMed ID: 12852346
[TBL] [Abstract][Full Text] [Related]
2. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
4. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
[TBL] [Abstract][Full Text] [Related]
5. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
Mielke F; Schneider-Obermeyer J; Dörner T
Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
[No Abstract] [Full Text] [Related]
6. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-induced vasculitis.
Dereure O; Navarro R; Rossi JF; Guilhou JJ
Dermatology; 2001; 203(1):83-4. PubMed ID: 11549810
[No Abstract] [Full Text] [Related]
8. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
9. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
Kang SP; Saif MW
J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853
[No Abstract] [Full Text] [Related]
10. Desensitization for hypersensitivity reactions to medications.
del Carmen Sancho M; Breslow R; Sloane D; Castells M
Chem Immunol Allergy; 2012; 97():217-33. PubMed ID: 22613865
[TBL] [Abstract][Full Text] [Related]
11. [Infusion reaction and anaphylaxis].
Yoshida K; Shiono M; Ishioka C
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1753-7. PubMed ID: 22083179
[TBL] [Abstract][Full Text] [Related]
12. Interstitial granulomatous dermatitis with arthritis associated with trastuzumab.
Martín G; Cañueto J; Santos-Briz A; Alonso G; Unamuno PD; Cruz JJ
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):493-4. PubMed ID: 19744176
[No Abstract] [Full Text] [Related]
13. Review of hypersensitivity reactions to antineoplastic agents.
Cortijo-Cascajares S; Jiménez-Cerezo MJ; Herreros de Tejada A
Farm Hosp; 2012; 36(3):148-58. PubMed ID: 22484106
[TBL] [Abstract][Full Text] [Related]
14. [Allergic reactions and pseudoallergies in surgical interventions with general anesthesia].
Sánchez Palacios A; Ortiz Ponce M; Rodríguez Pérez A
Allergol Immunopathol (Madr); 2000; 28(1):24-36. PubMed ID: 10757856
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
16. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
17. Prevention and management of cardiotoxicity from antineoplastic therapy.
Chanan-Khan A; Srinivasan S; Czuczman MS
J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
[TBL] [Abstract][Full Text] [Related]
18. [Specific adverse events caused by monoclonal antibodies, focusing on the prophylaxis and management].
Akiyama S
Nihon Rinsho; 2012 Dec; 70(12):2199-204. PubMed ID: 23259397
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.
González V; Salgueiro E; Jimeno FJ; Hidalgo A; Rubio T; Manso G
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):714-21. PubMed ID: 18340626
[TBL] [Abstract][Full Text] [Related]
20. Management of drug allergy.
De Swarte RD
Mod Treat; 1968 Sep; 5(5):792-813. PubMed ID: 4387995
[No Abstract] [Full Text] [Related]
[Next] [New Search]
